THE PREVALENCE OF METABOLIC SYNDROME IN SCHIZOPHRENIC PATIENTS IN THE NETHERLANDS (original) (raw)
Related papers
Journal of Psychiatric Research, 2009
Cross-sectional studies showed a high prevalence of metabolic syndrome in patients with schizophrenia.This study aimed to identify the incidence of metabolic syndrome and its reversal in a non-preselected cohort of chronic psychotic patients in routine practice in one year follow-up and to find variables to describe development and reversal of metabolic syndrome. This cohort study was conducted as part of a disease management program and patients were included if they had two complete assessments in a one year follow-up. We conducted two logistic regressions to find variables to describe the development of metabolic syndrome and the reversal of metabolic syndrome. At the time of the first assessment 35% (n = 92) of the 260 included patients had metabolic syndrome. Within one year 21 patients developed metabolic syndrome and 30 patients had it reversed. This was an incidence of 13% (21/168) and a reversal of 33% (30/92). Smoking, family history of cardiovascular diseases, and duration of disease >6 years was associated with a higher risk of developing metabolic syndrome as well as abdominal obesity and dyslipidemia. Patients with abdominal obesity had a smaller chance of reversing metabolic syndrome. Other variables included in the logistic regression such as receiving cardiovascular/antidiabetic drug treatment or duration of disease >6 years did not alter the risk of reversing the metabolic syndrome. Our study showed that the natural course of metabolic syndrome is dynamic. A considerable number of patients developed or reversed the metabolic syndrome in one year follow-up.
Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study
BMC Psychiatry, 2007
Background: Not only the prevalence, but also the progress of metabolic abnormalities in schizophrenic patients is of importance for treatment planning and policy making. However, there have been very few prospective studies of metabolic disturbance in schizophrenic patients. This study aimed to assess the progress of metabolic abnormalities in Thai individuals with schizophrenia by estimating their one-year incidence rate of metabolic syndrome (MetS).
Nigerian Journal of Psychiatry, 2010
The metabolic syndrome has been implicated in the increasing incidence of cardiovascular morbidity. The syndrome is commoner among patients with schizophrenia compared to the general population. Schizophrenia is a chronic condition in which morbidity and mortality may arise due to co-morbid cardiovascular disorders. The prevalence of the metabolic syndrome has not been studied in psychiatric patient populations in Nigeria.
Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
Caspian Journal of Internal Medicine, 2020
Background: This study was conducted to determine the prevalence of metabolic syndrome (Mets) in schizophrenic patients in a 6-month period of treatment with antipsychotic medications. Methods: In this study, 60 volunteer schizophrenic patients were included. At the onset and 6 months after treatment with antipsychotic medications, fasting blood sugar (FBS), serum triglyceride (TG), high density lipoprotein (HDL), weight, waist circumference (WC), and blood pressure were determined. We defined Mets according to ATPIII criteria. Results: After a 6-month treatment with antipsychotic drugs, the mean WC, serum TG, HDL, systolic and diastolic blood pressure increased but the changes of WC and HDL were statistically significant (p<0.05). We found that the percentage of patients with high WC, low HDL levels, and Mets increased after treatment which was statistically significant (p<0.05). Conclusion: It is recommended that nutritional and lifestyle changes intervention should be implanted for schizophrenic patients undergoing treatment.
Psychiatria Danubina
BACKGROUND: Metabolic syndrome and other cardiovascular risk factors are highly prevalent in people with schizophrenia. Metabolic syndrome can contribute to significant morbidity and premature mortality and should be accounted for in the treatment of mental disorders. Along with results of numerous investigations regarding metabolic syndrome, different issues have occurred. The aim of this article is to review literature regarding diagnostic and treatment of metabolic syndrome and point at some issues regarding diagnostic and treatment of metabolic syndrome in patients with psychotic disorders and in general population. CONTENT ANALYSIS OF LITERATURE: Literature research included structured searches of Medline and other publications on the subject of metabolic syndrome, particularly diagnostic and treatment of metabolic syndrome in patients with psychotic disorders and in general population. CONCLUSION: Despite numerous investigations of metabolic syndrome, many issues remain unclea...
Archives of Psychiatry and Psychotherapy, 2013
Aim. This study is dedicated to evaluation of the prevalence of metabolic syndrome and its components in patients with schizophrenia in Russia. Methods. 138 patients with schizophrenia who received antipsychotic medication and 138 mental healthy subjects from 1,561 bank employees cohort matched to schizophrenic patients by sex, age and body mass index were enrolled to the study. Fasting blood plasma levels of glucose, lipids, insulin, cortisol, prolactin concentrations were determined. Results. In comparison with control group, patients had significantly higher frequency of metabolic syndrome and abdominal type of obesity (according to NCEP ATP III and IDF criteria). In spite of lesser level of plasma glucose and total cholesterol, plasma insulin and triglycerides concentrations were higher in patients with schizophrenia. High density lipoprotein cholesterol concentration was lower in patients while arterial blood pressure level didn't differ between groups. Cortisol and prolactin levels were elevated in the patient group, but these hormones neither correlated with metabolic syndrome nor with any metabolic parameters studied. Discussion. The study conducted in Russia revealed the increased frequency of metabolic syndrome in schizophrenic patients in comparison with mental healthy cohort. The main disorders found in the patient group were abdominal obesity, insulin resistance and dyslipidemia. Conclusion. Results obtained in this study should be taken into account when developing of medical treatment of patients with schizophrenia.
The Prevalence of Metabolic Syndrome and Related Factors in Pa ents With Schizophrenia
Türk Psikiyatri Dergisi 2008; 19(2) Turkish Journal of Psychiatry Objective: The aim of this study was to examine the prevalence of metabolic syndrome (MS) and related factors in patients with schizophrenia at an outpatient clinic. Method: All 108 patients with schizophrenia or schizoaffective disorder that presented to the outpatient clinic between 12 May and 12 June 2006 were included in the study. Of the 108 patients, 100 whose biochemical analyses were completed were assessed. Results: The prevalence of MS was 21%, 34%, and 41% according to ATP III, ATP III-A, and IDF criteria, respectively. Increased waist circumference and low HDL level were frequent among the patients. The prevalence of MS increased with age. Mean age, duration of illness and duration of treatment were higher and family history of obesity was common in the patients with MS. Discussion: The prevalence of ATP III-defined MS in patients with schizophrenia was lower compared to that reported in other studies; however, the prevalence of MS was high based on ATP III-A and IDF criteria. Patients with schizophrenia are at increased risk for MS or related metabolic problems. In particular, when risk factors such as older age, female gender, long duration of illness and treatment, and family history of obesity exist, clinicians should examine the metabolic condition of the patient. Increased waist circumference and low HDL level are probably the best predictors of MS.
Drug Safety, 2006
The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic syndrome in European patients suffering from schizophrenia. Methods: All consecutive patients with schizophrenia at our university psychiatric hospital and affiliate services were entered in an extensive prospective metabolic study including an oral glucose tolerance test. The prevalence of the metabolic syndrome was assessed based on the National Cholesterol Education Program criteria (NCEP, Adult Treatment Protocol, ATP-III), adapted ATP-III criteria using a fasting glucose threshold of 100 mg/dl (AHA) and on the recently proposed criteria from the International Diabetes Federation (IDF). Results: The analysis of 430 patients showed a prevalence of the metabolic syndrome of 28.4% (ATP-III), 32.3% (ATP-III A) and 36% (IDF), respectively. The prevalence of the metabolic syndrome in our sample of patients with schizophrenia is at least twice as high compared to an age-adjusted community sample in Belgium. Conclusion: The metabolic syndrome is highly prevalent among treated patients with schizophrenia. It represents an important risk for cardiovascular and metabolic disorders. Assessment of the presence and monitoring of the associated risks of the metabolic syndrome should be part of the clinical management of patients treated with antipsychotics. D